In clinical studies the test showed a 97 percent sensitivity within 10 days post onset of symptoms and a 100 percent specificity on anterior nasal swabs, and a 96.1 percent sensitivity and a 99.3 percent specificity on nasopharyngeal swabs.
The Liaison SARS-CoV-2 Ag runs on the company’s Liaison XL platform.
Pages: 1 2